openPR Logo
Press release

Primary Biliary Cholangitis (PBC) Treatment Market Outlook 2016 To 2024 – Global Industry Growth Analysis

07-03-2017 03:31 PM CET | Health & Medicine

Press release from: Transparency Market Research

Primary Biliary Cholangitis (PBC) Treatment Market Outlook

Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes severe liver damage, resulting in cirrhosis at the later stage of the disease. The disease primarily affects women in their middle age. The lack of a definitive cure for primary biliary cholangitis (PBC) results in an immensely lucrative business opportunity to tap into this underserved market.

Obtain Report Details @ http://www.transparencymarketresearch.com/primary-biliary-cholangitis-treatment-market.html

Although presently the disease cannot be cured by medication, the progression of liver damage can be stalled with the help of a drug known as ursodeoxycholic acid (UDCA), the only FDA approved medication for the disease. Additionally, the symptoms of the disease in early stages which include itching and fatigue can be relieved with the aid of drugs such as antihistamines and opioid antagonists. However, if primary biliary cholangitis is diagnosed in later stages, the sole treatment option which remains viable for survival is liver transplantation. The improved diagnostic processes worldwide coupled with rise in patient awareness regarding treatment and physician check-ups upon experiencing symptomatic discomfort has led to lesser requirement of transplants. The improved scenario relating to the prognosis of primary biliary cholangitis has thus made medication a more popular course of treatment in comparison to liver transplants resulting in alleviating the progression of the disease.

Although the treatment with UDCA helps reduce advancement of liver destruction, the drug has shown to be ineffective in adequately reducing disease specific blood compounds (such as bilirubin) in over 40% patients. Moreover few patients have experienced intolerance to the drug. Thus, there is immense potential for a new cure and innovative drug to create a remedial breakthrough in the market due to the current unmet need of the patient population.

The global primary biliary cholangitis market can been segmented on the basis of type of treatment and by region. Based on type of treatment, the global market has been segmented into drugs and liver transplantation. The drugs segment has been further segmented into primary treatment (UDCA) and symptomatic relief treatment. The symptomatic relief segment includes drugs to aid in reduction of disease symptoms which includes antihistamines, Cholestyramine, antibacterials and opioid antagonists. In addition, a pipeline assessment has also been provided to assess the drugs undergoing early stage and late stage clinical trials.

Globally, the annual incidence of the disease is estimated to be between 0.7 and 49 cases per million-population and prevalence between 6.7 and 940 cases per million-population, the variance in cases primarily based on age and gender and geographic location. However, various peer reviewed articles have suggested that the incidence is gradually increasing worldwide. Geographically the market has been segmented into five regions, namely North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market for this disease is expected to be higher in North America and Europe owing to the higher prevalence and incidence of the disease in those regions. Primary Biliary Cholangitis is more prevalent in Northern Europe, North America and Latin America and less common in Eastern Asia, Africa, and Australia. In the U.S., PBC is among the top ten causes to undergo a liver transplant. The incidence of PBC is high in U.K as compared to other regions in Europe and thus U.K is an attractive business opportunity for research as well as trial studies and drug sales pertaining to this disease. Thus, the global market for PBC is driven by rise in incidence of primary biliary cholangitis, increased exposure to environmental triggers to the immune system such as pesticides to susceptible individuals and growth in faulty lifestyle related triggers such as alcoholism, smoking and obesity.

Fill The Form To Gain Deeper Insights On This Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14093

The key players in the market include Novartis AG, Actavis, Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., Siedco Pharmaceutical Co., and Teva Pharmaceuticals Inc. etc.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Biliary Cholangitis (PBC) Treatment Market Outlook 2016 To 2024 – Global Industry Growth Analysis here

News-ID: 606438 • Views: 200

More Releases from Transparency Market Research

Potassium Bicarbonate Market Technological breakthroughs, Value chain and stakeh …
Overview TMR’s report on the Potassium Bicarbonate Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Potassium Bicarbonate serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Potassium Bicarbonate over the forecast period. These indicators help businesses
Liquid Analytical Instruments Market Global Market Opportunity Assessment Study …
Overview TMR’s report on the Liquid Analytical Instruments Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Liquid Analytical Instruments serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Liquid Analytical Instruments over the forecast period. These
Boron Oxide Market Growth Prospects, Trends and Forecast up to 2023
Overview TMR’s report on the Boron Oxide Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Boron Oxide serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Boron Oxide over the forecast period. These indicators help businesses
Hydrochloric Acid Market to Witness a Pronounce Growth During 2016 - 2024
Overview TMR’s report on the Hydrochloric Acid Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Hydrochloric Acid serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Hydrochloric Acid over the forecast period. These indicators help businesses

All 5 Releases


More Releases for PBC

Global Linear Slides Market 2018 - SKF, PBC Linear, PHD Inc., igus
Apex Market Reports, recently published a detailed market research study focused on the “Linear Slides Market” across the global, regional and country level. The report provides 360° analysis of “Linear Slides Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Linear Slides on
Artificial Lung Market Key Players 2018 - Haemair Ltd, Lung Biotechnology PBC, a …
Artificial Lung Overview: Medical Devices sector report, “Artificial Lung - Medical Devices Pipeline Assessment, 2018" provides an overview of Artificial Lung currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start
Primary Biliary Cholangitis (PBC) Treatment Market to Witness Steady Growth thro …
Primary biliary cholangitis is also referred as primary biliary cirrhosis, is an autoimmune disease of liver that manifest into progressive cholestasis and lead to end-stage liver disease. Primary biliary cholangitis characterized by destruction of bile duct which transport the bile acid. Primary biliary cholangitis is detected in the late stage of disease. Primary biliary cirrhosis majorly seen in women’s in fourth or sixth decades of life. Primary biliary cholangitis generally
Primary Biliary Cholangitis (PBC) Treatment Market to increase rapidly by 2024
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes
Primary Biliary Cholangitis (PBC) Treatment Market : Key Trends and Forecast Res …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes
Primary Biliary Cholangitis (PBC) Treatment Market Players to Open Facilities Wo …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes